Kineta is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research.
Our research is focused on developing novel immune-modulating therapeutics and vaccine adjuvants targeting autoimmune and infectious diseases. Kineta’s AViiD™ Screening Platform is the foundation of our innate immune antiviral and adjuvant programs.
02/18/2016 - Washington’s heroin crisis: struggle to get help